Access the full text.
Sign up today, get DeepDyve free for 14 days.
Loading next page...
/lp/taylor-francis/antisense-oligonucleotide-pharmacokinetics-and-metabolism-1EczFdFpGs
References (76)
-
M. Butler, C. Hayes, A. Chappell, S. Murray, T. Yaksh, X. Hua (2005)
Spinal distribution and metabolism of 2′-O-(2-methoxyethyl)-modified oligonucleotides after intrathecal administration in ratsNeuroscience, 131
-
C. Senn, C. Hangartner, S. Moes, D. Guerini, K. Hofbauer (2005)
Central administration of small interfering RNAs in rats: a comparison with antisense oligonucleotides.European journal of pharmacology, 522 1-3
-
R. Geary, S. Henry, L. Grillone (2002)
FomivirsenClinical Pharmacokinetics, 41
-
R. Yu, Tae-Won Kim, A. Hong, Tanya Watanabe, H. Gaus, R. Geary (2007)
Cross-Species Pharmacokinetic Comparison from Mouse to Man of a Second-Generation Antisense Oligonucleotide, ISIS 301012, Targeting Human Apolipoprotein B-100Drug Metabolism and Disposition, 35
-
D. SmetdeM., C. Meenken, J. HornvandenG. (1999)
Fomivirsen: a phosphorothioate oligunucleotide for the treatment of CMV retinitisEuropean Journal of Public Health
-
• Excellent review of basic principles for oligonucleotide ADME -
P. Miner, M. Wedel, B. Bane, J. Bradley (2004)
An enema formulation of alicaforsen, an antisense inhibitor of intercellular adhesion molecule‐1, in the treatment of chronic, unremitting pouchitisAlimentary Pharmacology & Therapeutics, 19
-
Mike Templin, A. Levin, M. Graham, P. Åberg, B. Axelsson, Madeline Butler, Richard Geary, C. Bennett (2000)
Pharmacokinetic and toxicity profile of a phosphorothioate oligonucleotide following inhalation delivery to lung in mice.Antisense & nucleic acid drug development, 10 5
-
L. Tillman, R. Geary, G. Hardee (2008)
Oral delivery of antisense oligonucleotides in man.Journal of pharmaceutical sciences, 97 1
-
Ruiwen Zhang, Zhihong Lu, Hui Zhao, Xueshu Zhang, R. Diasio, I. Habuš, Zhiwei Jiang, R. Iyer, Dong Yu, Sudhir Agrawal (1995)
In vivo stability, disposition and metabolism of a "hybrid" oligonucleotide phosphorothioate in rats.Biochemical pharmacology, 50 4
-
S. Mani, C. Rudin, K. Kunkel, J. Holmlund, R. Geary, H. Kindler, F. Dorr, M. Ratain (2002)
Phase I clinical and pharmacokinetic study of protein kinase C-alpha antisense oligonucleotide ISIS 3521 administered in combination with 5-fluorouracil and leucovorin in patients with advanced cancer.Clinical cancer research : an official journal of the American Association for Cancer Research, 8 4
-
R. Griffey, M. Greig, H. Gaus, K. Liu, D. Monteith, M. Winniman, L. Cummins (1997)
Characterization of oligonucleotide metabolism in vivo via liquid chromatography/electrospray tandem mass spectrometry with a quadrupole ion trap mass spectrometer.Journal of mass spectrometry : JMS, 32 3
-
S. Agrawal, J. Temsamani, W. Galbraith, J. Tang (1995)
Pharmacokinetics of Antisense OligonucleotidesClinical Pharmacokinetics, 28
-
P. Lorenz, T. Misteli, B. Baker, C. Bennett, D. Spector (2000)
Nucleocytoplasmic shuttling: a novel in vivo property of antisense phosphorothioate oligodeoxynucleotides.Nucleic acids research, 28 2
-
(2004)
In vitro protein binding and drug interaction studies of an antisense oligonucleotide (aso), Isis 113715, targeting human Ptb1b Mrna -
Shahid Ali, Sherry Leonard, Cindy Kukoly, W. Metzger, Wallace Wooles, Jacqueline M, C. Ginty, Makoto Tanaka, A. Sandrasagra, Jonathan Nyce (2001)
Absorption, distribution, metabolism, and excretion of a respirable antisense oligonucleotide for asthma.American journal of respiratory and critical care medicine, 163 4
-
Richard Geary, Janet Leeds, J. Fitchett, T. Burckin, L. Truong, Charles Spainhour, Moire Creek, Arthur Levin (1997)
Pharmacokinetics and metabolism in mice of a phosphorothioate oligonucleotide antisense inhibitor of C-raf-1 kinase expression.Drug metabolism and disposition: the biological fate of chemicals, 25 11
-
P. Miner, Richard Geary, John Matson, Emil Chuang, Shuting Xia, Brenda Baker, M. Wedel (2006)
Bioavailability and therapeutic activity of alicaforsen (ISIS 2302) administered as a rectal retention enema to subjects with active ulcerative colitisAlimentary Pharmacology & Therapeutics, 23
-
First comprehensive report of cross-species pharmacodynamic relationships to pharmacokinetics for a second generation antisense oligonucleotide -
M. Manoharan, K. Rajeev (2007)
Utilizing Chemistry to Harness RNA Interference Pathways for Therapeutics: Chemically Modified siRNAs and Antagomirs -
D. Braasch, Z. Paroo, A. Constantinescu, Gang Ren, O. Oz, R. Mason, D. Corey (2004)
Biodistribution of phosphodiester and phosphorothioate siRNA.Bioorganic & medicinal chemistry letters, 14 5
-
K. Kilk, Ű. Langel (2005)
Cellular delivery of peptide nucleic acid by cell-penetrating peptides.Methods in molecular biology, 298
-
M. Graham, S. Crooke, D. Monteith, S. Cooper, K. Lemonidis, K. Stecker, Michael Martin, R. Crooke (1998)
In vivo distribution and metabolism of a phosphorothioate oligonucleotide within rat liver after intravenous administration.The Journal of pharmacology and experimental therapeutics, 286 1
-
R. Yu, R. Geary, A. Siwkowski, A. Levin (2007)
Pharmacokinetic/Pharmacodynamic Properties ofPhosphorothioate 2'-O-(2-Methoxyethyl)-ModifiedAntisense Oligonucleotides in Animals and Man -
R. Zhang, R. Diasio, Z. Lu, T. Liu, Z. Jiang, W. Galbraith, S. Agrawal (1995)
Pharmacokinetics and tissue distribution in rats of an oligodeoxynucleotide phosphorothioate (GEM 91) developed as a therapeutic agent for human immunodeficiency virus type-1.Biochemical pharmacology, 49 7
-
A. Amantana, P. Iversen (2005)
Pharmacokinetics and biodistribution of phosphorodiamidate morpholino antisense oligomers.Current opinion in pharmacology, 5 5
-
J. Phillips, S. Craig, D. Bayley, R. Christian, R. Geary, P. Nicklin (1997)
Pharmacokinetics, metabolism, and elimination of a 20-mer phosphorothioate oligodeoxynucleotide (CGP 69846A) after intravenous and subcutaneous administration.Biochemical pharmacology, 54 6
-
M. Khaitov, V. Akimov, E. Faizuloev, Nikonov Aa, L. Alexeev, Zverev Vv, L. Dubuske (2007)
Inhibition of Respiratory Syncytial Virus (RSV) Replication in Cell Culture by Small Interfering RNA (siRNA)The Journal of Allergy and Clinical Immunology, 119
-
R. Yu, R. Geary, D. Monteith, J. Matson, L. Truong, J. Fitchett, A. Levin (2004)
Tissue disposition of 2'-O-(2-methoxy) ethyl modified antisense oligonucleotides in monkeys.Journal of pharmaceutical sciences, 93 1
-
M. Graham, S. Crooke, K. Lemonidis, H. Gaus, M. Templin, R. Crooke (2001)
Hepatic distribution of a phosphorothioate oligodeoxynucleotide within rodents following intravenous administration.Biochemical pharmacology, 62 3
-
J. Karras, J. Crosby, M. Guha, David Tung, Doreen Miller, W. Gaarde, R. Geary, B. Monia, S. Gregory (2007)
Anti-Inflammatory Activity of Inhaled IL-4 Receptor-α Antisense Oligonucleotide in MiceAmerican Journal of Respiratory Cell and Molecular Biology, 36
-
P. Cossum, H. Sasmor, D. Dellinger, L. Truong, L. Cummins, S. Owens, P. Markham, J. Shea, S. Crooke (1993)
Disposition of the 14C-labeled phosphorothioate oligonucleotide ISIS 2105 after intravenous administration to rats.The Journal of pharmacology and experimental therapeutics, 267 3
-
Akin Akinc, A. Zumbuehl, A. Zumbuehl, Michael Goldberg, Elizaveta Leshchiner, V. Busini, Naushad Hossain, S. Bacallado, David Nguyen, Jason Fuller, R. Álvarez, A. Borodovsky, T. Borland, Rainer Constien, A. Fougerolles, J. Dorkin, K. Jayaprakash, M. Jayaraman, Matthias John, V. Koteliansky, M. Manoharan, L. Nechev, June Qin, T. Racie, D. Raitcheva, K. Rajeev, D. Sah, J. Soutschek, I. Toudjarska, H. Vornlocher, Tracy Zimmermann, R. Langer, Dustin Anderson (2008)
A combinatorial library of lipid-like materials for delivery of RNAi therapeuticsNature Biotechnology, 26
-
Ming Zhang, I. Creese (1993)
Antisense oligodeoxynucleotide reduces brain dopamine D2 receptors: Behavioral correlatesNeuroscience Letters, 161
-
V. Arora, G. Devi, P. Iversen (2004)
Neutrally charged phosphorodiamidate morpholino antisense oligomers: uptake, efficacy and pharmacokinetics.Current pharmaceutical biotechnology, 5 5
-
D. Burt, C. Tickle (2003)
Encyclopedia of Molecular Cell Biology and Molecular Medicine -
G. Lendvai, I. Velikyan, S. Estrada, B. Eriksson, B. Långström, M. Bergström (2008)
Biodistribution of 68Ga-labeled LNA-DNA mixmer antisense oligonucleotides for rat chromogranin-A.Oligonucleotides, 18 1
-
Hong Zhang, J. Cook, J. Nickel, R. Yu, K. Stecker, K. Myers, N. Dean (2000)
Reduction of liver Fas expression by an antisense oligonucleotide protects mice from fulminant hepatitisNature Biotechnology, 18
-
A. Adjei, G. Dy, C. Erlichman, J. Reid, J. Sloan, H. Pitot, S. Alberts, R. Goldberg, L. Hanson, P. Atherton, Tanya Watanabe, R. Geary, J. Holmlund, F. Dorr (2003)
A phase I trial of ISIS 2503, an antisense inhibitor of H-ras, in combination with gemcitabine in patients with advanced cancer.Clinical cancer research : an official journal of the American Association for Cancer Research, 9 1
-
A. Levin, R. Yu, R. Geary (2007)
Basic Principles of the Pharmacokinetics of Antisense Oligonucleotide Drugs -
P. Cossum, L. Truong, S. Owens, P. Markham, J. Shea, S. Crooke (1994)
Pharmacokinetics of a 14C-labeled phosphorothioate oligonucleotide, ISIS 2105, after intradermal administration to rats.The Journal of pharmacology and experimental therapeutics, 269 1
-
R. Yu, K. Lemonidis, M. Graham, J. Matson, R. Crooke, D. Tribble, M. Wedel, A. Levin, R. Geary (2009)
Cross-species comparison of in vivo PK/PD relationships for second-generation antisense oligonucleotides targeting apolipoprotein B-100.Biochemical pharmacology, 77 5
-
J. Kastelein, M. Wedel, B. Baker, John Su, J. Bradley, R. Yu, E. Chuang, M. Graham, R. Crooke (2006)
Potent Reduction of Apolipoprotein B and Low-Density Lipoprotein Cholesterol by Short-Term Administration of an Antisense Inhibitor of Apolipoprotein BCirculation, 114
-
R. Geary, Tanya Watanabe, L. Truong, Sue Freier, E. Lesnik, N. Sioufi, H. Sasmor, M. Manoharan, A. Levin (2001)
Pharmacokinetic properties of 2'-O-(2-methoxyethyl)-modified oligonucleotide analogs in rats.The Journal of pharmacology and experimental therapeutics, 296 3
-
Richard Smith, Richard Smith, T. Miller, K. Yamanaka, B. Monia, T. Condon, G. Hung, C. Lobsiger, Chris Ward, Melissa McAlonis-Downes, Hongbing Wei, E. Wancewicz, C. Bennett, D. Cleveland (2006)
Antisense oligonucleotide therapy for neurodegenerative disease.The Journal of clinical investigation, 116 8
-
(2006)
RNAi in drug discovery & therapeutics – combining tools and technologies to improve delivery and efficacy of key compounds -
S. Agrawal, J. Temsamani, Jin-yang Tang (1991)
Pharmacokinetics, biodistribution, and stability of oligodeoxynucleotide phosphorothioates in mice.Proceedings of the National Academy of Sciences of the United States of America, 88 17
-
M. Manoharan (2004)
RNA interference and chemically modified small interfering RNAs.Current opinion in chemical biology, 8 6
-
M. Frank-Kamenetsky, A. Grefhorst, Norma Anderson, T. Racie, B. Bramlage, Akin Akinc, David Butler, K. Charissé, Robert Dorkin, Yupeng Fan, C. Gamba‐Vitalo, P. Hadwiger, M. Jayaraman, Matthias John, K. Jayaprakash, Martin Maier, L. Nechev, K. Rajeev, T. Read, I. Röhl, J. Soutschek, P. Tan, Jamie Wong, Gang Wang, Tracy Zimmermann, A. Fougerolles, H. Vornlocher, R. Langer, Daniel Anderson, M. Manoharan, V. Koteliansky, J. Horton, K. Fitzgerald (2008)
Therapeutic RNAi targeting PCSK9 acutely lowers plasma cholesterol in rodents and LDL cholesterol in nonhuman primatesProceedings of the National Academy of Sciences, 105
-
A. Levin (1999)
A review of the issues in the pharmacokinetics and toxicology of phosphorothioate antisense oligonucleotides.Biochimica et biophysica acta, 1489 1
-
R. Geary, J. Leeds, S. Henry, D. Monteith, A. Levin (1997)
Antisense oligonucleotide inhibitors for the treatment of cancer: 1. Pharmacokinetic properties of phosphorothioate oligodeoxynucleotides.Anti-cancer drug design, 12 5
-
(2001)
Second generation antisense oligonucleotide pharmacokinetics and mass balance following intravenous administration in rats in Society Of Toxicology -
J. Crosby, M. Guha, David Tung, Doreen Miller, B. Bender, T. Condon, C. York-Defalco, R. Geary, B. Monia, J. Karras, S. Gregory (2007)
Inhaled CD86 Antisense Oligonucleotide Suppresses Pulmonary Inflammation and Airway Hyper-Responsiveness in Allergic MiceJournal of Pharmacology and Experimental Therapeutics, 321
-
R. Crooke, M. Graham, M. Martin, K. Lemonidis, T. Wyrzykiewiecz, L. Cummins (2000)
Metabolism of antisense oligonucleotides in rat liver homogenates.The Journal of pharmacology and experimental therapeutics, 292 1
-
M. Wójcik, M. Cieślak, W. Stec, J. Goding, M. Koziołkiewicz (2007)
Nucleotide pyrophosphatase/phosphodiesterase 1 is responsible for degradation of antisense phosphorothioate oligonucleotides.Oligonucleotides, 17 1
-
R. Griffey, M. Greig, H. Gaus, Kenneth Liu, D. Monteith, M. Winniman, L. Cummins (1997)
Characterization of Oligonucleotide MetabolismIn Vivovia Liquid Chromatography/Electrospray Tandem Mass Spectrometry with a Quadrupole Ion Trap Mass SpectrometerJournal of Mass Spectrometry, 32
-
J. Moore, K. Seiter, J. Kolitz, W. Stock, F. Giles, M. Kalaycio, D. Zenk, G. Marcucci (2006)
A Phase II study of Bcl-2 antisense (oblimersen sodium) combined with gemtuzumab ozogamicin in older patients with acute myeloid leukemia in first relapse.Leukemia research, 30 7
-
R. Yu, R. Geary, J. Flaim, G. Riley, D. Tribble, A. Vanvliet, M. Wedel (2009)
Lack of Pharmacokinetic Interaction of Mipomersen Sodium (ISIS 301012), a 2′-—O-Methoxyethyl Modified Antisense Oligonucleotide Targeting Apolipoprotein B-100 Messenger RNA, with Simvastatin and EzetimibeClinical Pharmacokinetics, 48
-
R. Geary, R. Yu, Tanya Watanabe, S. Henry, G. Hardee, A. Chappell, J. Matson, H. Sasmor, L. Cummins, A. Levin (2003)
Pharmacokinetics of a tumor necrosis factor-alpha phosphorothioate 2'-O-(2-methoxyethyl) modified antisense oligonucleotide: comparison across species.Drug metabolism and disposition: the biological fate of chemicals, 31 11
-
G. Hardee, L. Tillman, R. Geary (2007)
Routes and Formulations for Delivery of Antisense Oligonucleotides -
O. Khatsenko, R. Morgan, L. Truong, C. York-Defalco, H. Sasmor, B. Conklin, R. Geary (2000)
Absorption of antisense oligonucleotides in rat intestine: effect of chemistry and length.Antisense & nucleic acid drug development, 10 1
-
T. Vickers, S. Koo, C. Bennett, S. Crooke, N. Dean, B. Baker (2003)
Efficient Reduction of Target RNAs by Small Interfering RNA and RNase H-dependent Antisense AgentsThe Journal of Biological Chemistry, 278
-
Tanya Watanabe, R. Geary, A. Levin (2006)
Plasma protein binding of an antisense oligonucleotide targeting human ICAM-1 (ISIS 2302).Oligonucleotides, 16 2
-
S. Reich, J. Fosnot, A. Kuroki, W. Tang, Xiangya Yang, A. Maguire, J. Bennett, M. Tolentino (2003)
Small interfering RNA (siRNA) targeting VEGF effectively inhibits ocular neovascularization in a mouse model.Molecular vision, 9
-
J. Leeds, R. Geary, S. Henry, J. Glover, W. Shanahan, J. Fitchett, T. Burckin, LoAnne Tmong, A. Levin (1997)
Pharmacokinetic Properties of Phosphorothioate OligonucleotidesNucleosides, Nucleotides & Nucleic Acids, 16
-
R. Geary, O. Khatsenko, K. Bunker, R. Crooke, M. Moore, T. Burckin, L. Truong, H. Sasmor, A. Levin (2001)
Absolute bioavailability of 2'-O-(2-methoxyethyl)-modified antisense oligonucleotides following intraduodenal instillation in rats.The Journal of pharmacology and experimental therapeutics, 296 3
-
R. Yu, H. Zhang, R. Geary, M. Graham, L. Masarjian, K. Lemonidis, R. Crooke, N. Dean, A. Levin (2001)
Pharmacokinetics and pharmacodynamics of an antisense phosphorothioate oligonucleotide targeting Fas mRNA in mice.The Journal of pharmacology and experimental therapeutics, 296 2
-
(1999)
A pharmacokinetic study of intravitreal fomivirsen (VitraveneTM) in patients with CMVR -
J. Karras, J. Crosby, M. Guha, David Tung, Doreen Miller, W. Gaarde, R. Geary, B. Monia, S. Gregory (2007)
Anti-inflammatory activity of inhaled IL-4 receptor-alpha antisense oligonucleotide in mice.American journal of respiratory cell and molecular biology, 36 3
-
V. Arora, Derek Knapp, M. Reddy, D. Weller, P. Iversen (2002)
Bioavailability and efficacy of antisense morpholino oligomers targeted to c-myc and cytochrome P-450 3A2 following oral administration in rats.Journal of pharmaceutical sciences, 91 4
-
J. Leeds, R. Geary (1998)
Pharmacokinetic Properties of Phosphorothioate Oligonucleotides in HumansHandbook of experimental pharmacology, 131
-
Tracy Zimmermann, Amy Lee, Akin Akinc, B. Bramlage, D. Bumcrot, M. Fedoruk, J. Harborth, J. Heyes, L. Jeffs, Matthias John, A. Judge, Kieu Lam, K. Mcclintock, L. Nechev, Lorne Palmer, T. Racie, I. Röhl, S. Seiffert, Sumi Shanmugam, Vandana Sood, J. Soutschek, I. Toudjarska, Amanda Wheat, Ed Yaworski, William Zedalis, V. Koteliansky, M. Manoharan, H. Vornlocher, I. Maclachlan (2006)
RNAi-mediated gene silencing in non-human primatesNature, 441
-
S. Bhanot (2007)
Developing Antisense Drugs for Metabolic Diseases: A Novel Therapeutic Approach -
K. Sewell, R. Geary, B. Baker, J. Glover, T. Mant, R. Yu, J. Tami, F. Dorr (2002)
Phase I Trial of ISIS 104838, a 2′-Methoxyethyl Modified Antisense Oligonucleotide Targeting Tumor Necrosis Factor-αJournal of Pharmacology and Experimental Therapeutics, 303
-
R. Geary, J. Bradley, Tanya Watanabe, Younggil Kwon, M. Wedel, J. Lier, A. Vliet (2006)
Lack of Pharmacokinetic Interaction for ISIS 113715, a 2′-0-Methoxyethyl Modified Antisense Oligonucleotide Targeting Protein Tyrosine Phosphatase 1B Messenger RNA, with Oral Antidiabetic Compounds Metformin, Glipizide or RosiglitazoneClinical Pharmacokinetics, 45
-
H. Gaus, S. Owens, M. Winniman, Scott Cooper, L. Cummins (1997)
On-line HPLC electrospray mass spectrometry of phosphorothioate oligonucleotide metabolites.Analytical chemistry, 69 3
- Publisher
- Taylor & Francis
- Copyright
- ©© Informa UK Ltd
- ISSN
- 1744-7607
- eISSN
- 1742-5255
- DOI
- 10.1517/17425250902877680
- Publisher site
- See Article on Publisher Site
Abstract
Background: The use of oligonucleotides as therapeutic agents has elicited a great deal of interest. Basic understanding and evaluation of the pharmacokinetic properties of oligonucleotides is foundational to their appropriate design and application. Objective: To review the primary pharmacokinetic properties that drive successful use and delivery of oligonucleotides. Methods: The primary data set available in the published literature for summarizing the pharmacokinetic properties of oligonucleotides exists for single strand phosphorothioate antisense oligonucleotides and their chimeric chemical modifications (second generation). Where possible, data from other classes of compounds are contrasted with this base class. Results/conclusion: Although there are several different classes of oligonucleotides being developed as therapeutic agents, their pharmacokinetic properties by class are primarily a function of their backbone chemistry and the resulting chemical relationship to biological stability and plasma protein binding properties.
Journal
Expert Opinion on Drug Metabolism & Toxicology – Taylor & Francis
Published: Apr 1, 2009
Keywords: ADME; mRNA; oligoneucleotide; pharmacokinetics